Multiple Myeloma (MM) is a malignant plasma cell disorder with an unmet medical need, in
particular for relapsed and refractory patients. Molecules within deregulated signaling …

Multiple myeloma (MM) is characterised by the expansion of monoclonal immunoglobulin-
secreting plasma cells. Despite recent advances in systemic and supportive therapy, it …

Introduction: The development of proteasome inhibitor (PI) and immunomodulatory drugs
(IMiDs) and advances in supportive care have considerably changed the treatment …

Multiple myeloma is a common hematological malignancy of plasma cells, the terminally
differentiated B cells that secrete antibodies as part of the adaptive immune response …

Multiple myeloma (MM) is a plasma cell malignancy that is still considered to be incurable in
most cases. A dominant mutation cluster has been identified in RAS/RAF genes …

Multiple myeloma (MM) is a devastating malignancy of antibody-producing plasma cells. In
the absence of a single unifying genetic event contributing to disease manifestation, efforts …

ABSTRACT Introduction: Transcription factors (TFs) are convergence points of signaling
cascades that coordinate cell differentiation, proliferation, survival, and migration; and are …

Activating mutations of the MAPK pathway are reported in over half of myeloma tumors.
Experience with MEK inhibitors in solid tumors suggest that although tumors harboring …

Multiple Myeloma is a molecularly heterogeneous disease with a high degree of genomic
instability in which specific genetic changes can be linked to clinical presentation and …

Simple Summary In the last decade, proteasome inhibitors (PIs) have become a standard for
the treatment of multiple myeloma (MM). As a consequence of the pleiotropic effects of PIs …